Courtesy of SeekingAlpha and Benzinga.com ETF Professor

Another day, another set of fresh all-time highs for the major biotechnology ETFs. Biotech investors were treated to the same feat in late March, but as healthcare has continued to be a market-leading sector, faster-moving biotech funds have flourished.

Heading into the start of trading Thursday the Market Vectors Biotech ETF (BBH) was leading the way with a year-to-date gain of over 21 percent. The iShares Nasdaq Biotechnology Index Fund (IBB), the largest biotech ETF by assets, has not been a slouch with a gain of 20.5 percent while the First Trust NYSE Arca Biotechnology Index Fund(FBT) has returned 19.7 percent this year.

The SPDR S&P Biotech ETF (XBI), an almost equal-weight play on the sector, has jumped 15.2 percent.

All are higher by at least 1.3 percent in midday trading and all are touching new all-time highs. With performances like that combined with the notion that four biotech ETFs are probably enough, it is easy for other funds to get lost in the shuffle.

Such is life for the PowerShares Dynamic Biotechnology & Genome Portfolio (PBE), though that does not mean PBE is a bad ETF. Quite the contrary. PBE was up 14.8 percent year-to-date at the start of trading Thursday. Less than months shy of its eighth birthday, PBE also joined the new all-time high club today.

In a crowded field of biotech ETFs, a fund such as PBE that does not reside among the previously mentioned big four needs to stand out in some way. PBE does that. For starters, PBE is not dominated by the big four biotech stocks. Those being Amgen (AMGN), Biogen (BIIB),Celgene (CELG) and Gilead Sciences (GILD). Continue reading →